Fluence Analytics Included in CB Insights’ Inaugural List of Top 50 Global Advanced Manufacturing Startups
Fluence Analytics, a leader in continuous analytics and process control solutions for the polymer and biopharmaceutical industries, was recently named as a Top 50 global advanced manufacturing startup by CB Insights. CB Insights is an industry leading software company that enables some of the world’s best companies to discover, understand, and make better technology decisions with confidence. The Inaugural Advanced Manufacturing 50 is a list of the most promising private advanced manufacturing companies in the world, and the 50 companies were segmented into 16 different cohorts.
Fluence Analytics was one of three companies featured in the R&D Optimization category. Beyond optimizing R&D for polymer and biopharma customers, ACOMP by Fluence Analytics also delivers process manufacturing optimization. ACOMP currently enables the development and production of next-generation polymer materials and will soon support the scale up of chemical recycling (plastic upcycling) technologies.
The final 50 companies were selected from among a pool of more than 6,000 companies who either submitted an application or were nominated. The finalists all have demonstrated an ability to promote faster, safer, more efficient, and more sustainable R&D and production processes. The CB Insights research team selected the final list of the 50 companies based on several factors that include R&D activity, proprietary Mosaic scores, market potential, business relationships, investor profile, news sentiment analysis, competitive landscape, team strength, and tech novelty.
Fluence Analytics is a Houston-based startup that delivers process monitoring, optimization and control products to polymer and biopharmaceutical customers worldwide. The company has two product lines, ACOMP and ARGEN. ACOMP is a polymer smart manufacturing system that plays a leading role in digital transformation plans by generating never-before-seen data sets that improve product quality and yields, reduce cycle times, and reduce energy consumption and material waste. ARGEN accelerates and optimizes the development of novel biotherapeutics with the use of unique time dependent data sets that provide insights into how thermal and mechanical stress impact the stability of biologics, which is a vital criteria for releasing new therapies to patients worldwide.